HomeCompareCRARY vs PFE

CRARY vs PFE: Dividend Comparison 2026

CRARY yields 6.70% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CRARY wins by $34143.16M in total portfolio value
10 years
CRARY
CRARY
● Live price
6.70%
Share price
$9.27
Annual div
$0.62
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34143.21M
Annual income
$33,191,291,037.41
Full CRARY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CRARY vs PFE

📍 CRARY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCRARYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CRARY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CRARY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRARY
Annual income on $10K today (after 15% tax)
$569.35/yr
After 10yr DRIP, annual income (after tax)
$28,212,597,381.80/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, CRARY beats the other by $28,212,575,061.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRARY + PFE for your $10,000?

CRARY: 50%PFE: 50%
100% PFE50/50100% CRARY
Portfolio after 10yr
$17071.63M
Annual income
$16,595,658,648.07/yr
Blended yield
97.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CRARY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-0.2
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRARY buys
2
PFE buys
0
PoliticianChamberTickerTypeAmountDate
Bruce Westerman🏢 House$CRARY▼ Sell$1,001 - $15,0002025-04-21
Bruce Westerman🏢 House$CRARY▲ Buy$1,001 - $15,0002025-03-03
Daniel Goldman🏢 House$CRARY▼ Sell$1,001 - $15,0002023-07-10
Greg Gianforte🏢 House$CRARY▲ Buy$1,001 - $15,0002020-11-13
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCRARYPFE
Forward yield6.70%6.13%
Annual dividend / share$0.62$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$34143.21M$49.6K
Annual income after 10y$33,191,291,037.41$26,258.71
Total dividends collected$34077.66M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: CRARY vs PFE ($10,000, DRIP)

YearCRARY PortfolioCRARY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$12,040$1,339.65$9,153$693.39+$2.9KCRARY
2$15,897$3,014.76$8,593$849.25+$7.3KCRARY
3$24,451$7,440.56$8,336$1,066.78+$16.1KCRARY
4$47,553$21,390.47$8,437$1,384.80+$39.1KCRARY
5$128,640$77,759.20$9,013$1,875.40+$119.6KCRARY
6$530,834$393,189.17$10,306$2,680.72+$520.5KCRARY
7$3,600,692$3,032,699.06$12,820$4,101.38+$3.59MCRARY
8$42,303,276$38,450,535.77$17,673$6,826.70+$42.29MCRARY
9$889,642,002$844,377,497.02$27,543$12,591.86+$889.61MCRARY
10$34,143,207,980$33,191,291,037.41$49,560$26,258.71+$34143.16MCRARY

CRARY vs PFE: Complete Analysis 2026

CRARYStock

Crédit Agricole S.A. provides retail, corporate, insurance, and investment banking products and services worldwide. It operates through Asset Gathering; Large Customers; Specialised Financial Services; French Retail Banking - LCL; and International Retail Banking. The company offers banking products and services, including savings and current accounts and deposits, finance, payments, and flow management services; consumer finance products; and banking and specialized financial services. It also provides wealth management services that allow individual customers to manage, protect, and transfer their assets, as well as other asset management services; and savings/retirement, death and disability/creditor/group, and property and casualty insurance products. In addition, the company offers financing solutions for property and equipment investment and renewal requirements; trade receivable financing and management solutions for corporates; and financing services for renewable energy and public infrastructure projects, as well as leasing services. Further, it provides investment banking, structured finance, international trade finance, commercial banking, capital market, and syndication services; and asset servicing solutions for investment products, as well as various asset classes, such as execution, clearing, forex, security lending and borrowing, custody, depositary bank, fund administration, middle-office outsourcing solutions, and fund distribution support and issuer services. The company serves retail customers, corporates, banks and financial institutions, government agencies, and local authorities. Crédit Agricole S.A. was founded in 1894 and is headquartered in Montrouge, France. Crédit Agricole S.A. operates as a subsidiary of SAS Rue La Boétie.

Full CRARY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CRARY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRARY vs SCHDCRARY vs JEPICRARY vs OCRARY vs KOCRARY vs MAINCRARY vs JNJCRARY vs MRKCRARY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.